Germany: CJEU asked to clarify functional definition issue
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: CJEU asked to clarify functional definition issue

Recently, the 14th Senate of the German Federal Patent Court referred new questions to the CJEU on the criteria for Article 3(a) of the SPC Regulation (EC) No. 469/2009 (decision 14 W (pat) 12/17; CJEU: C-650/17) to clarify when a functional definition refers to the product in question.

In this case, the claims of the basic patent EP 1 084 705 B1 refer to treatment of Diabetes mellitus by administration of DPIV-inhibitors based on the inventors' recognition that inhibition of the enzyme DPIV generally allows for lowering of blood glucose. The SPC was requested for sitagliptin, a DPIV-inhibitor marketed for treatment of Diabetes mellitus. The basic patent refers to DPIV inhibitors and points out that other DPIV inhibitors may be used as well, however does not disclose sitaglipin individually. Sitagliptin is protected by a later filed composition of matter patent.

The situation is thus comparable with the CJEU Eli Lilly decision (C-493/12) where the claims were directed to the genus of Neutrokine-alpha antibodies, but the product in question, tabalumab being a Neutrokine-alpha antibody was not individually disclosed in the claims or the specification and had been developed after the filing date of the basic patent. In this case the CJEU had ruled that functional features can protect a product under Article 3(a) if the claim refers implicitly, necessarily and specifically to the product. However, courts and patent offices have struggled with this test. The UK, for example, has taken a rather generous approach, whilst authorities in the Netherlands, France and Germany seem to require an individualized disclosure of the product in the description or consider Eli Lilly to be limited to biologics.

In its referring decision the Senate acknowledges that sitagliptin is a DPIV-inhibitor and would thus be within the extent of protection conferred by Article 69 EPC. However, according to the Senate's interpretation following the rejection of the infringement test by Medeva (CJEU C332/10) it would not be sufficient for the purpose of Article 3 (a) that the product in question, namely sitagliptin, falls within the extent of protection (Schutzbereich) conferred by the claims. It would rather be required that the product is disclosed specifically enough to form the subject matter (Schutzgegenstand) of the claims, which in the absence of an individualized disclosure of sitagliptin in the basic patent would not be the case.

In view of the divergent interpretation of the CJEU's case law by the national courts and patent offices, the Senate referred the questions whether the product is protected by a basic patent in force only if it belongs to the protected subject-matter as defined by the claims and whether it is not sufficient that the product in question meets the functional definition in the claims, but is not individualized in the basic patent. The outcome of this referral together with the pending referral (C121/17) hopefully will bring more clarity for the interpretation of Article 3(a).

Annelie Wünsche

Dirk Bühler


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article